[1] | Sankaranarayanan R. Overview of cervical cancer in the developing world. FIGO 26 th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 (Suppl 1): S205-10. |
|
[2] | Okonufua F. HPV vaccine and prevention of cervical cancer in Africa. Afr J Reprod Health 2007; 11:7-12. |
|
[3] | World Health Organization. Nigeria:Human Papillomavirus and Related Cancers, Fact Sheet 2014. WHO/ICO HPV Information Centre.Institut Català d’Oncologia Avda. Gran Via de l’Hospitalet, 199-20308908 L’Hospitalet de Llobregat (Barcelona, Spain).e-mail: info@hpvcentre.net.internet adress:www.hpvcentre.net. |
|
[4] | Walker ARP, Michelow PM, Walker BF. Cervix cancer in African women in Durban, South Africa. International Journal of Gynecology & Obstetrics 2002; 79:45-46. |
|
[5] | Buga GA. Cervical cancer awareness and risk factors among female university students. East Afr Med J 1998; 75(7):411-16. |
|
[6] | Ajayi IO, Adewole IF. Knowledge and attitude of out patients' attendants in Nigeria to cervical cancer. Central Afr J Med 1998; 44(2):41-44. |
|
[7] | Wellensiek N, Moodley M, Moodley J, Nkwanyana N. Knowledge of cervical cancer screening and use of cervical screening facilities among women from various socioeconomic backgrounds in Durban, Kwazulu-Natal, South Africa. Int J Gynecol Cancer 2002; 12: 376-82. |
|
[8] | Anorlu RI, Banjo AAF, Odoemhum C. Cervical cancer and cervical cancer screening: level of awareness in women attending a primary health care facility in Lagos. Nig Postgrad Med J 2000; 70: 25-28. |
|
[9] | Frazer H. Human papilloma virus vaccine. Int J Gynecol Obstet 2006; 94:381-8. |
|
[10] | Ugwu E O, Obi S N, Ezechukwu P C, Okafor I I, Ugwu A O. Acceptability of human papilloma virus vaccine and cervical cancer screening among female health-care workers in Enugu, Southeast Nigeria. Niger J Clin Pract 2013; 16: 249-52. |
|
[11] | Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol, 2005; 6, 271-8. |
|
[12] | Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Rotell- Martin CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papilloma virus types 16 and 18: Follow-up from a randomised control trial. Lancet 2006; 367:1247-55. |
|
[13] | World Health Organization Human papillomavirus vaccines WHO position paper. Weekly Epidemiol Rec. 2009; 15 (84):117-132. |
|
[14] | Federal Ministry of Health. Nigeria Cancer Control Plan 2008-2013. Abuja: Federal Ministry of Health, Abuja, 2008:1-40. |
|
[15] | de Sanjosé S, Serrano B, Castellsagué X, Brotons M, Muñoz J, Bruni L, et al. Human Papillomavirus (HPV) and Related Cancers in the Global Alliance for Vaccines and Immunization (GAVI) Countries. A WHO/ICO HPV Information Centre Report. Vaccine, 2012; 30 (Suppl 4). Available at: www.who.int/hpvcentre Accessed 24/12/2014. |
|
[16] | GAVI. Countries eligible for support. Available at: http://www.gavi.org/support/apply/countries-eligible-for-support/.Accessed 25/07/2014. |
|
[17] | GAVI. Human papillomavirus vaccine support. Available at: http://www.gavi.org/support/nvs/human-papillomavirus-vaccine-support/. Accessed 25/07/2014. |
|
[18] | Ezegwui HU, Onoh RC, Ikeako LC, Onyebuchi A, Umeora OUJ, Ezeonu P, Ibekwe P.Investigating Maternal Mortality in a Public Teaching Hospital, Abakaliki, Ebonyi State, Nigeria. Ann Med Health Sci Res. 2013; 3(1): 75-80. |
|
[19] | Anorlu RI, Banjo AAF, Odoemhum C. Cervical cancer and cervical cancer screening: level of awareness in women attending a primary health care facility in Lagos. Nig Postgrad Med J 2000; 70: 25-28. |
|
[20] | Naing L, Winn T, Rusli BN. Practical issues in calculating the sample size for prevalence studies. Archives of Orofacial Sciences. 2006; 1: 9-14. |
|
[21] | Bingham A, Drake JK, La Montagne DS. Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings Arch Pediatr Adolesc Med .2009; 163:455-61. |
|
[22] | Songthap A, Pitisuttithum P, Kaewkungwal J, Fungladda W, Bussaratid V. Knowledge, attitudes, and acceptability of a human papilloma virus vaccine among students, parents and teachers in Thailand. Southeast Asian J Trop Med Public Health. 2012 Mar; 43(2):340-53. |
|
[23] | Nwozor C. M. and Oragudosi A. L. Awareness and Uptake of Cervical Cancer Screening among Women in Onitsha, South-East, Nig Greener J Med Sci .2013; 3 (8): 283-288. |
|
[24] | Ezem B.U. Awareness and uptake of cervical cancer screening in Owerri, South-Eastern Nigeria. Ann Afr Med. 2007;6:94-8. |
|
[25] | Eze J.N., Umeora O.U., Obuna J.A., Egwuatu V.E., Ejikeme B.N (2012).Cervical cancer awareness and cervical screening uptake at Mater Misericordiae Hospital, Afikpo, Southeast Nigeria. Ann Afr Med. 11: 238-43. |
|
[26] | Yen CF, Chen SF, Lin LP, Hsu SW, Chang MJ, Wu CL, Lin JD. The acceptability of human papillomavirus (HPV) vaccination among women with physical disabilities. Res Dev Disabil. 2011 Sep-Oct; 32(5):2020-6. |
|